Angiotensin-converting enzyme inhibitor prevents plasminogen activator inhibitor-1 expression in a rat model with cardiovascular remodeling induced by chronic inhibition of nitric oxide synthesis

Journal of Molecular and Cellular Cardiology

Volumn 32, Issue 1, 2000, Pages 73-83

  Katoh, Makoto ^a,b   Egashira, Kensuke ^b   Mitsui, Takashi ^a   Chishima, Susumu ^a   Takeshita, Akira ^b   Narita, Hiroshi ^a  

^a MITSUBISHI TANABE PHARMA CORPORATION   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

Angiotensin converting enzyme; Nitric oxide; Plasminogen activator inhibitor 1; Vascular remodeling

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; IMIDAPRIL; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTA; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG EFFECT; EXTRACELLULAR MATRIX; FIBRINOLYSIS; HEART VENTRICLE REMODELING; IMMUNOREACTIVITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ANIMALIA;

EID: 0033955769     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmcc.1999.1053     Document Type: Article

References (43)

1. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 327:1987;524-526.
2. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J Clin Invest. 83:1989;1774-1777.
3. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L- arginine in the hypercholesterolemic rabbit. J Clin Invest. 90:1992;1168-1172.
4. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 329:1993;2002-2012.
5. Tsao PS, McEvoy LM, Drexler H, Butcher EC, Cooke JP. Enhanced endothelial adhesiveness in hyperÍcholesterolemia is attenuated by L-arginine. Circulation. 89:1994;2176-2182.
6. von der Leyen HE, Gibbons GH, Morishita R, Lewis NP, Zhang L, Nakajima M, Kaneda Y, Cooke JP, Dzau VJ. Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene. Proc Natl Acad Sci USA. 92:1995;1137-1141.
7. Griendling KK, Alexander RW. Endothelial control of the cardiovascular system: recent advances. Faseb J. 10:1996;283-292.
8. Drexler H. Endothelial dysfunction: clinical implications. Prog Cardiovasc Dis. 39:1997;287-324.
9. Zeiher AM, Drexler H, Saurbier B, Just H. Endothelium-mediated coronary blood flow modulation in humans. Effects of age, atherosclerosis, hyperÍcholesterolemia, and hypertension. J Clin Invest. 92:1993;652-662.
10. Egashira K, Inou T, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Kuga T, Urabe Y, Takeshita A. Effects of age on endothelium-dependent vasodilation of resistance coronary artery by acetylcholine in humans. Circulation. 88:1993;77-81.
11. Egashira K, Inou T, Hirooka Y, Yamada A, Maruoka Y, Kai H, Sugimachi M, Suzuki S, Takeshita A. Impaired coronary blood flow response to acetylcholine in patients with coronary risk factors and proximal atherosclerotic lesions. J Clin Invest. 91:1993;29-37.
12. Egashira K, Suzuki S, Hirooka Y, Kai H, Sugimachi M, Imaizumi T, Takeshita A. Impaired endothelium-dependent vasodilation of large epicardial and resistance coronary arteries in patients with essential hypertension. Different responses to acetylcholine and substance P. Hypertension. 25:1995;201-206.
13. Ito A, Egashira K, Kadokami T, Fukumoto Y, Takayanagi T, Nakaike R, Kuga T, Sueishi K, Shimokawa H, Takeshita A. Chronic inhibition of endothelium-derived nitric oxide synthesis causes coronary microvascular structural changes and hyperreactivity to serotonin in pigs. Circulation. 92:1995;2636-2644.
14. Numaguchi K, Egashira K, Takemoto M, Kadokami T, Shimokawa H, Sueishi K, Takeshita A. Chronic inhibition of nitric oxide synthesis causes coronary microvascular remodeling in rats. Hypertension. 26:1995;957-962.
15. Kadokami T, Egashira K, Kuwata K, Fukumoto Y, Kozai T, Yasutake H, Kuga T, Shimokawa H, Sueishi K, Takeshita A. Altered serotonin receptor subtypes mediate coronary microvascular hyperreactivity in pigs with chronic inhibition of nitric oxide synthesis. Circulation. 94:1996;182-189.
16. Katoh M, Egashira K, Usui M, Ichiki T, Tomita H, Shimokawa H, Rakugi H, Takeshita A. Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ Res. 83:1998;743-751.
17. Tomita H, Egashira K, Ohara Y, Takemoto M, Koyanagi M, Katoh M, Yamamoto H, Tamaki K, Shimokawa H, Takeshita A. Early induction of transforming growth factor-beta via angiotensin II type 1 receptors contributes to cardiac fibrosis induced by long-term blockade of nitric oxide synthesis in rats. Hypertension. 32:1998;273-279.
18. Arnal JF, Warin L, Michel JB. Determinants of aortic cyclic guanosine monophosphate in hypertension induced by chronic inhibition of nitric oxide synthase. J Clin Invest. 90:1992;647-652.
19. Takemoto M, Egashira K, Tomita H, Usui M, Okamoto H, Kitabatake A, Shimokawa H, Sueishi K, Takeshita A. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension. 30:1997;1621-1627.
20. Takemoto M, Egashira K, Usui M, Numaguchi K, Tomita H, Tsutsui H, Shimokawa H, Sueishi K, Takeshita A. Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J Clin Invest. 99:1997;278-287.
21. van Kleef EM, Smits JF, De Mey JG, Cleutjens JP, Lombardi DM, Schwartz SM, Daemen MJ. Alpha 1-adrenoreceptor blockade reduces the angiotensin II-induced vascular smooth muscle cell DNA synthesis in the rat thoracic aorta and carotid artery. Circ Res. 70:1992;1122-1127.
22. van Krimpen C, Schoemaker RG, Cleutjens JP, Smits JF, Struyker Boudier HA, Bosman FT, Daemen MJ. Angiotensin I converting enzyme inhibitors and cardiac remodeling. Basic Res Cardiol. 1:1991;149-155.
23. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH, Vaughan DE. Stimulation of plasÍminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation. 87:1993;1969-1973.
24. Hamdan AD, Quist WC, Gagne JB, Feener EP. Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation. 93:1996;1073-1078.
25. van Leeuwen RT, Kol A, Andreotti F, Kluft C, Maseri A, Sperti G. Angiotensin II increases plasÍminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells. Circulation. 90:1994;362-368.
26. Feener EP, Northrup JM, Aiello LP, King GL. Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J Clin Invest. 95:1995;1353-1362.
27. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest. 95:1995;995-1001.
28. Loskutoff DJ, Sawdey M, Mimuro J. Type 1 plasÍminogen activator inhibitor. Prog Hemost Thromb. 9:1989;87-115.
29. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest. 88:1991;1067-1072.
30. Juhan Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 70:1993;138-143.
31. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med. 332:1995;635-641.
32. Yamamoto H, Ueno H, Ooshima A, Takeshita A. Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-beta) type II receptor completely and specifically abolishes diverse signaling by TGF-beta in vascular wall cells in primary culture. J Biol Chem. 271:1996;16253-16259.
33. Romanic AM, Madri JA. Extracellular matrix-degrading proteinases in the nervous system. Brain Pathol. 4:1994;145-156.
34. Yu K, Lu D, Paddy MR, Lenk SE, Raizada MK. Angiotensin II regulation of plasminogen activator inhibitor-1 gene expression in neurons of normotensive and spontaneously hypertensive rat brains. Endocrinology. 137:1996;2503-2513.
35. Landin K, Tengborn L, Smith U. Elevated fibrinogen and plasminogen activator inhibitor (PAI-1) in hypertension are related to metabolic risk factors for cardiovascular disease. J Intern Med. 227:1990;273-278.
36. Nordby G, Haaland A, Os I. Evidence of decreased fibrinolytic activity in hypertensive premenopausal women. Scand J Clin Lab Invest. 52:1992;275-281.
37. Bouchie JL, Hansen H, Feener EP. Natriuretic factors and nitric oxide suppress plasminogen activator inhibitor-1 expression in vascular smooth muscle cells. Role of cGMP in the regulation of the plasminogen system. Arterioscler Thromb Vasc Biol. 18:1998;1771-1779.
38. Newby DE, Wright RA, Dawson P, Ludlam CA, Boon NA, Fox KA, Webb DJ. The L-arginine/nitric oxide pathway contributes to the acute release of tissue plasminogen activator in vivo in man. Cardiovasc Res. 38:1998;485-492.
39. Stein CM, Brown N, Vaughan DE, Lang CC, Wood AJ. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. J Am Coll Cardiol. 32:1998;117-122.
40. Nishimura H, Tsuji H, Masuda H, Nakagawa K, Nakahara Y, Kitamura H, Kasahara T, Sugano T, Yoshizumi M, Sawada S, Nakagawa M. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost. 77:1997;1189-1195.
41. Kerins DM, Hao Q, Vaughan DE. Angiotensin induction of PAI-1 expression in endothelial cells is mediated by the hexapeptide angiotensin IV. J Clin Invest. 96:1995;2515-2520.
42. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 33:1999;389-395.
43. Kubo-Inoue M, Egashira K, Takemoto M, Katoh M. Activation of angiotensin-converting enzyme is the development of cyclic blood flow variations (arterial thrombosis) in stenosed carotid arteries of rats with chronic inhibition of nitric oxide synthesis. Circulation. 96:1997;I-352 (abstract).